Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications
- 30 September 1993
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 72 (10) , D75-D79
- https://doi.org/10.1016/0002-9149(93)90015-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cost and health implications of cholesterol lowering.Circulation, 1992
- Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.BMJ, 1991
- Expected gains in life expectancy from various coronary heart disease risk factor modifications.Circulation, 1991
- Cost-effectiveness of HMG-CoA Reductase Inhibition for Primary and Secondary Prevention of Coronary Heart DiseasePublished by American Medical Association (AMA) ,1991
- Long-term impact of smoking cessation on the incidence of coronary heart disease.American Journal of Public Health, 1990
- Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model.Circulation, 1989
- Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model.American Journal of Public Health, 1987
- Evidence That Men With Familial Hypercholesterolemia Can Avoid Early Coronary DeathPublished by American Medical Association (AMA) ,1986
- Coronary artery disease in heterozygous familial hypercholesterolemiaAtherosclerosis, 1982
- Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis A comparative study of genetic and environmental factors in 274 heterozygous casesAtherosclerosis, 1976